Darvon and Darvocet Lawsuit filed against FDA by Public Cititzen
The consumer watchdog group, Public Citizen, has filed a Darvon / Darvocet lawsuit against the FDA as a result of their failure to act on a petition filed in 2006, which called for the painkiller to be removed from the market. The petition claims that Darvon, Darvocet and other generic painkillers containing propoxyphene have been linked to thousands of deaths, are highly addictive and are no more effective than safer alternatives.
Darvocet and Darvon are narcotic pain drugs that contain the chemical propoxyphene. The drug is also available as a generic from several different pharmaceutical companies. It is approved for treatment of mild to moderate pain, and is often prescribed to manage pain after surgery.
Public Citizen originally filed a petition with the FDA on February 28, 2006, requesting that a Darvon / Darvocet recall be issued to phase the drug off of the market. The petition indicated that more than 2,000 accidental deaths were linked to the medication since 1981. In addition, it is a relatively weak painkiller, which Public Citizen indicates is no more effective than common drugs like ibuprofen or acetaminophen for many kinds of pain.
Earlier this year, Public Citizen also filed a lawsuit against the FDA as a result of their failure to act on a different petition filed as a result of side effects of Levaquin, Cipro and other antibiotics which increase the risk of serious tendon ruptures. The consumer group has a strong history of identifying dangerous drugs, such as Vioxx, ephedra, Bextra, Rezulin, Baycol and Propulsid.
DAVRON AND DARVOCET LAWSUITS
The product liability lawyers at Saiontz & Kirk, P.A. are reviewing the potential for Davron and Darvocet lawsuits for individuals who have suffered injuries which may be a side effect of the painkiller. If you, a friend or family member have suffered an overdose or death after taking Darvocet, Davron or another painkiller containing propoxyphene, request a free consultation and claim evaluation.
